PARP means poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins.
- Advertising -
This helps to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs or other substances in the environment.
PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA.
- Advertising -
Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways.
Complete report on PARP Inhibitor Market spread across 80 pages with providing 4 company profiles, 10 tables and 37 charts is now available at www.marketreportsonline.com/734491.html.
PARP inhibitors play an effective maintenance role in current cancer-combating strategies with its superior effect to that of existing ovarian cancer treatment. Currently, Talazoparib and Veliparib are in Phase III clinical trials and Rucaparib, Olaparib and Niraparib are approved PARP drugs which are currently present in the market for ovarian cancer.
PARP inhibitors improve progression-free survival in women with recurrent ovarian cancer, sensitive to platinum.
The U.S. is the major market of PARP inhibitor supported by PARPi for ovarian cancer in the market. The U.S. region is likely to experience further growth of PARP inhibitor market with upcoming PARP inhibitors and growing cases of cancer.
The global PARP inhibitor market is expected to grow in future due to increasing ageing population, rising cancer incidences, rise in health expenditure and improving economic conditions and vast unmet medical need. Key trends in this market include a combination of PARP and immuno therapy, increasing awareness, development of biomarkers and strong research and development efforts.
However, there are some factors which can hinder the market growth including side effects, resistance to PARP inhibitors and regulatory challenges.
The report “Global PARP Inhibitor Market: Industry Analysis & Outlook (2018-2025)” provides an extensive research and detailed analysis of the present market along with future outlook. ThePARP inhibitor market report discusses the major growth drivers and challenges of the market, covering the U.S.
and Europe region along with the global market. The four major players: Tesaro Inc., Clovis Oncology, AstraZeneca and Abbvie Inc.
are being profiled along with their key financials and strategies for growth.
Major Points from Table of Contents:
1. Market Overview
1.1 DNA Damage Response (DDR)
1.2 DNA Repair Pathways
1.3 PARP Inhibitor
1.4 Inhibiting PARP Mechanism
1.5 PARP for Cancer Treatment
1.6 PARP Inhibitor Drugs
2. Global Market Analysis
2.1 Global PARP Inhibitor Market
2.2 Global PARP Inhibitor Market by Drug Type
3. Regional Markets
3.1 The U.S.
3.2 European Union
4. Market Dynamics
4.1 Growth Drivers
4.2 Key Trends & Developments
5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 PARP Inhibitor Development by Company
6. Company Profiles
Category: Market Research Publishers and RetailersCompany profile: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.
For more information: